Developer docs
API playgroundTry for free, no card

Search company profiles

Tessa Therapeutics

Full company profile

uuid0000uyk

Namestring
Tessa Therapeutics
Websiteurl
tessacell.com
Company typeenum
Private
Founded yearint
2001
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
cell therapy, T cell therapy, solid tumor immunotherapy, autologous cell therapy, oncology biologics
Industry5 codes
1CAR-T & TCR-T Therapies
CodeHLAAABACPrimaryYes
2Cell Therapy Developers (Autologous)
CodeHLAAABAAPrimaryNo
3Dendritic Cell & Other APC-based Therapies
CodeHLAAABAFPrimaryNo
4Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
CodeHLAAABALPrimaryNo
5Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
CodeHLAAANAKPrimaryNo
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tessa Therapeutics develops autologous T cell-based immunotherapies designed to treat solid tumors. The company's platform leverages virus-specific T cells and related cell engineering approaches to create patient-specific cell therapies for oncology indications. Operations span clinical development, cell therapy manufacturing, and translational research from its Singapore base.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Autologous T cell therapy for solid tumors
CategoryCell therapy / oncology biologics
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Adaptimmune Therapeutics
TypeDirect peer
Description

Adaptimmune develops SPEAR T cell receptor (TCR-T) therapies for solid tumors, directly overlapping with Tessa's T cell receptor approach. Both target solid tumor indications using engineered autologous T cells.

2Fate Therapeutics
TypeBroad incumbent
Description

Fate Therapeutics is a leader in iPSC-derived off-the-shelf NK and T cell therapies. It is a broader cell therapy incumbent pursuing off-the-shelf alternatives to Tessa's autologous T cell strategy.

3Iovance Biotherapeutics
TypeDirect peer
Description

Iovance develops tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, the closest direct competitor to Tessa's autologous T cell platform. Both companies target the same unmet need of cell therapy for solid tumors.

4Allogene Therapeutics
TypeBroad incumbent
Description

Allogene is a leading allogeneic CAR-T developer with a broad pipeline across hematologic and solid tumors. It is a broader incumbent in cell therapy whose off-the-shelf approach contrasts with Tessa's autologous strategy.

5Carsgen Therapeutics
TypeRegional player
Description

Carsgen is a China-based CAR-T developer with solid tumor programs, comparable to Tessa in modality and target indication. It serves primarily the APAC market and provides regional competitive context.

6Takara Bio
TypeRegional player
Description

Takara Bio is a Japan-based cell therapy and gene therapy developer with engineered T cell programs. It is a regional peer with comparable cell therapy capabilities in the APAC market where Tessa operates.

7Cellectis
TypeEmerging player
Description

Cellectis develops allogeneic CAR-T therapies using TALEN gene editing. It is an emerging player in engineered cell therapy that overlaps with Tessa's cell engineering approach but with an allogeneic rather than autologous focus.

8Sorrento Therapeutics
TypeDirect peer
Description

Sorrento is developing CAR-T and other cell therapy approaches including for solid tumors. Its diversified pipeline includes directly comparable autologous cell therapy programs.

9Marker Therapeutics
TypeDirect peer
Description

Marker Therapeutics develops multi-tumor-associated antigen-specific T cell therapies for solid tumors and hematologic malignancies. Its non-engineered, multi-antigen T cell platform overlaps conceptually with Tessa's T cell approach.

10Tmunity Therapeutics
TypeEmerging player
Description

Tmunity develops next-generation CAR-T and engineered T cell therapies, including programs in solid tumors. It is an emerging player in the same engineered T cell space as Tessa.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tessa Therapeutics

Cell Therapytessacell.com

Tessa Therapeutics firmographics

Firmographics
Name
Tessa Therapeutics
Website
https://tessacell.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Tessa Therapeutics industry classification

Industry
Product category
Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
CAR-T & TCR-T Therapies (HLAAABAC)
akta.pro secondary industries
Cell Therapy Developers (Autologous) (HLAAABAA), Dendritic Cell & Other APC-based Therapies (HLAAABAF), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

  • Cell therapy
  • T cell therapy
  • Solid tumor immunotherapy
  • Autologous cell therapy
  • Oncology biologics

Where Tessa Therapeutics is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Markets served

Tessa Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Tessa Therapeutics product offering

Product offering

Core offering

Tessa Therapeutics develops autologous T cell-based immunotherapies designed to treat solid tumors. The company's platform leverages virus-specific T cells and related cell engineering approaches to create patient-specific cell therapies for oncology indications. Operations span clinical development, cell therapy manufacturing, and translational research from its Singapore base.

Differentiator

Problem solved

Functional benefit

Products and services

  • Autologous T cell therapy for solid tumors

Companies that use Tessa Therapeutics

Customer profile

Ideal customer profiles2 records

Tessa Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tessa Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves2 records

Expansion highlights4 records

Tessa Therapeutics competitors and assessment

Company assessment

Direct peers

  • Adaptimmune Therapeutics: Adaptimmune develops SPEAR T cell receptor (TCR-T) therapies for solid tumors, directly overlapping with Tessa's T cell receptor approach. Both target solid tumor indications using engineered autologous T cells.
  • Iovance Biotherapeutics: Iovance develops tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, the closest direct competitor to Tessa's autologous T cell platform. Both companies target the same unmet need of cell therapy for solid tumors.
  • Sorrento Therapeutics: Sorrento is developing CAR-T and other cell therapy approaches including for solid tumors. Its diversified pipeline includes directly comparable autologous cell therapy programs.
  • Marker Therapeutics: Marker Therapeutics develops multi-tumor-associated antigen-specific T cell therapies for solid tumors and hematologic malignancies. Its non-engineered, multi-antigen T cell platform overlaps conceptually with Tessa's T cell approach.

Broad incumbents

  • Fate Therapeutics: Fate Therapeutics is a leader in iPSC-derived off-the-shelf NK and T cell therapies. It is a broader cell therapy incumbent pursuing off-the-shelf alternatives to Tessa's autologous T cell strategy.
  • Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with a broad pipeline across hematologic and solid tumors. It is a broader incumbent in cell therapy whose off-the-shelf approach contrasts with Tessa's autologous strategy.

Regional players

  • Carsgen Therapeutics: Carsgen is a China-based CAR-T developer with solid tumor programs, comparable to Tessa in modality and target indication. It serves primarily the APAC market and provides regional competitive context.
  • Takara Bio: Takara Bio is a Japan-based cell therapy and gene therapy developer with engineered T cell programs. It is a regional peer with comparable cell therapy capabilities in the APAC market where Tessa operates.

Emerging players

  • Cellectis: Cellectis develops allogeneic CAR-T therapies using TALEN gene editing. It is an emerging player in engineered cell therapy that overlaps with Tessa's cell engineering approach but with an allogeneic rather than autologous focus.
  • Tmunity Therapeutics: Tmunity develops next-generation CAR-T and engineered T cell therapies, including programs in solid tumors. It is an emerging player in the same engineered T cell space as Tessa.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Tessa Therapeutics social profiles

Digital presence

Tessa Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tessa Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Tessa Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tessa Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tessa Therapeutics

What does Tessa Therapeutics do?

Tessa Therapeutics develops autologous T cell-based immunotherapies designed to treat solid tumors. The company's platform leverages virus-specific T cells and related cell engineering approaches to create patient-specific cell therapies for oncology indications. Operations span clinical development, cell therapy manufacturing, and translational research from its Singapore base.

Is Tessa Therapeutics a public or private company?

Tessa Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tessa Therapeutics founded?

Tessa Therapeutics was founded in 2001. It employs 101 to 250 people.

Where is Tessa Therapeutics based?

Tessa Therapeutics is headquartered in Singapore, Singapore, in the Asia region.

Who are Tessa Therapeutics's main competitors?

Direct peers on record are Adaptimmune Therapeutics, Iovance Biotherapeutics, Sorrento Therapeutics and Marker Therapeutics. Broad incumbents are Fate Therapeutics and Allogene Therapeutics. Regional players are Carsgen Therapeutics and Takara Bio. Emerging players are Cellectis and Tmunity Therapeutics.

Does Tessa Therapeutics have an API?

No public API is recorded for Tessa Therapeutics.

What industry is Tessa Therapeutics in?

Tessa Therapeutics's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer InstituteTessa Therapeutics entered a CRADA with the U.S. National Cancer Institute to study its TT11X allogeneic CD30.CAR-EBVST therapy in non-Hodgkin lymphoma. Phase 1 data showed a 79% overall response rate and 43% complete response in CD30-positive Hodgkin lymphoma patients. The company plans to expand trials to other CD30-positive subtypes.GlobeNewswireTessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and ExpositionTessa Therapeutics announced three abstracts accepted for presentation at ASH 2022, including two oral podium presentations on its autologous CD30.CAR-T therapy (TT11) and allogeneic CD30.CAR EBVST therapy (TT11X). The data show an overall response rate of 73.3% in relapsed or refractory classical Hodgkin lymphoma patients and no GVHD in over 300 allogeneic recipients.trib.alTessa Therapeutics takes in $126M for cell therapies, and more biotech financingsSeveral biotechnology companies, including Tessa Therapeutics, Charm Therapeutics, and Code Biotherapeutics, secured significant funding rounds ranging from $22 million to $126 million to advance their drug discovery and clinical development programs. These investments support diverse therapeutic approaches such as cell therapies for cancer, AI-driven protein structure prediction, synthetic DNA delivery, and radiopharmaceuticals for neuroendocrine cancers. The financing activity highlights continued investor interest in specialized biotech sectors despite broader market challenges.BioSpaceTessa Therapeutics Completes US$126 Million Financing Led by Polaris PartnersTessa Therapeutics completed a US$126 million Series A financing round led by Polaris Partners, with participation from existing investors including Temasek, EDBI, Heliconia Capital, and Heritas Capital. The company plans to utilize the proceeds to advance the clinical development of its autologous TT11 and allogeneic TT11X cell therapy programs for hematological malignancies and solid tumors.PR NewswireTessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 StudyTessa Therapeutics announced enrollment completion of a 12-patient pilot cohort in its Phase 2 trial for relapsed/refractory Classical Hodgkin Lymphoma using an autologous CD30 CAR-T therapy. The pivotal cohort of 82 patients is planned to begin enrollment in the second half of 2021, following rapid pilot enrollment completed in under three months. The therapy previously demonstrated a 59% complete response rate in heavily pre-treated patients with no neurotoxicity or grade 3 cytokine release syndrome, and has received both RMAT designation from the FDA and PRIME designation from the European Medicines Agency.PR NewswireTessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy TrialTessa Therapeutics announced the successful completion of dosing for the first patient cohort (n=3) in a Phase I dose escalation study evaluating its allogeneic CD30-CAR EBVST therapy (TT11X) for CD30+ lymphoma at Baylor College of Medicine. The therapy demonstrated a favorable safety profile with no graft-versus-host disease or severe adverse events reported in the initial patients treated at Houston Methodist Hospital. The company indicated longer-term plans to expand this allogeneic platform to target solid tumors, where significant patient need exists.PR NewswireTessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T TherapyTessa Therapeutics received PRIME designation from the European Medicines Agency for its autologous CD30 CAR-T therapy targeting relapsed or refractory classical Hodgkin Lymphoma. Phase I/II trial data showed complete tumor disappearance in approximately 60% of patients at the highest dose level without the serious toxicities associated with other CAR-T therapies. The company plans to initiate a multi-center pivotal trial in 2021 across more than 20 cancer centers in the US and Europe.PR NewswireTessa Therapeutics Appoints David McIntyre as Chief Financial OfficerTessa Therapeutics appointed David McIntyre as its new Chief Financial Officer. McIntyre brings over 25 years of global financial, operational, and legal experience, having previously served as CFO at AVITA Medical and as a partner at life sciences venture capital firm Apple Tree Partners. The appointment is intended to strengthen Tessa's leadership as the company advances its cell therapy pipeline for cancer treatment through late-stage clinical development.PR NewswireTessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin LymphomaTessa Therapeutics announced positive results from two investigator-sponsored Phase 1/2 trials evaluating autologous CD30 CAR-T cell therapy in 41 patients with relapsed or refractory Hodgkin lymphoma, published in the Journal of Clinical Oncology. The trials demonstrated a 94% one-year survival rate, 61% durable complete response in evaluable patients, and a 72% overall response rate in patients receiving fludarabine-based lymphodepletion, with no life-threatening complications observed. Tessa has licensed the technology from Baylor College of Medicine and University of North Carolina and plans to initiate a company-sponsored regulatory Phase 2 trial while exploring expansion to CD30+ non-Hodgkin lymphomas.PR NewswireTessa Therapeutics Announces New Executive LeadershipTessa Therapeutics, a Singapore-based clinical-stage cell therapy company, announced leadership changes with Jeffrey H. Buchalter appointed as Chief Executive Officer and Göran A. Ando becoming Chairman of the Board, effective immediately. Current Chairman Teo Ming Kian stepped down as of May 1, 2020, while co-founder Andrew Khoo will remain on the Board. The company stated the transition positions Tessa for its next phase of development, including advancement of its clinical and research pipelines and completion of its own GMP manufacturing facility.